rawfin.tv
AbCellera Biologics (ABCL) Shifts Focus with ABCL635 Phase II Menopause Therapy
Top StoriesstocksAI Generated

AbCellera Biologics (ABCL) Shifts Focus with ABCL635 Phase II Menopause Therapy

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

AbCellera Biologics (ABCL) appears to be shifting its business model by advancing ABCL635, a nonhormonal menopause therapy, into Phase II trials. This strategic move could redefine the company's future direction and market focus.

ABCLbiotechnologydrug developmentbusiness modelclinical trials

Related Articles

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

stocks
EQT to Acquire Cleanaway Waste for $6.5 Billion

EQT to Acquire Cleanaway Waste for $6.5 Billion

stocks
S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

stocks
US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

stocks